Menu
As early as 1982, research on Photodynamic Therapy (PDT) began, where Katarina was one of the pioneers. At that time, the technology was relatively new and primarily suitable for superficial tumors. A research team at the Department of Physics at Lund University led the project that would later become SpectraCure.
Katarina is a medical doctor specialized in oncology. For over 30 years, she has worked at Skåne University Hospital, providing her with extensive experience in tumor treatment and prostate cancer therapy. Over the years, she has realized that many patients experience side effects after treatment, affecting their quality of life. Therefore, she sees significant potential in the company’s treatment method, which is both focal and can be tailored for each patient, while also being minimally invasive. This has the potential to reduce the risk of side effects for the patient.
Katarina’s extensive knowledge in both PDT and tumor treatment is of great importance for the board’s work.
Don’t miss the full interview with Katarina Svanberg!
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.